Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention
IMAGE-AF
2 other identifiers
interventional
400
1 country
1
Brief Summary
Atrial fibrillation (AF) is a major public health problem. The efficacy of the existing techniques is limited in the more aggressive forms. It is therefore necessary to develop approaches, in particular the identification of relevant biomarkers, to prevent the onset, recurrence or progression of AF in at-risk patients. The objective of this study is to describe the longitudinal metabolic and biomolecular signature of AF in patients eligible for cardiac ablation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2025
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 21, 2024
CompletedFirst Posted
Study publicly available on registry
December 16, 2024
CompletedStudy Start
First participant enrolled
March 10, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 1, 2029
June 9, 2026
May 1, 2026
4.6 years
November 21, 2024
June 4, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Biomarkers T1
The individuation of biomarkers uniquely present in AF patients - compared to control groups.
Day 0
Biomarkers T2
The individuation of biomarkers uniquely present in AF patients - compared to control groups.
Day 1
Biomarkers 2
The identification of biomarkers predictive of the risk of AF recurrence
12 months
Secondary Outcomes (2)
Algorithm
Month 12
Atrial electroanatomy and apneas
Immediately after the procedure
Study Arms (2)
Patients with FA
OTHERPatient with a documented Fibrillation Atrial within the last 18 months
Patients without FA
OTHERPatient without Fibrillation Atrial
Interventions
Eligibility Criteria
You may qualify if:
- Age ≥ 18 years, all genders, and ethnic origins
- Free, informed, and written consent signed
- Person affiliated to or benefiting from a social security scheme
You may not qualify if:
- Age \< 18 years
- Lack of informed consent
- Gestating women (pregnancy test carried out as part of care for FA patients, contraception, or menopause for women in control groups)
- Persons under administrative or judicial protection
- Endocarditis or pericarditis in progress or within the 3 last months
- Active tumor pathology (benign or malignant)
- Chronic inflammation or autoimmune disease
- Chronic liver disease
- Myocardial infarction within the last 8 weeks
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital of Bordeaux
Pessac, 33604, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nicolas DERVAL
University Hospital, Bordeaux
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 21, 2024
First Posted
December 16, 2024
Study Start
March 10, 2025
Primary Completion (Estimated)
October 1, 2029
Study Completion (Estimated)
October 1, 2029
Last Updated
June 9, 2026
Record last verified: 2026-05